Back to search

Article

Longitudinal follow-up of SARS-CoV-2 vaccine- induced antibody responses in patients with multiple sclerosis treated with anti-CD20 therapy

2026-06-15

Abstract excerpt

<title>Abstract</title> <p>B-cell–depleting anti-CD20 therapies are widely used in multiple sclerosis (MS) but impair humoral immune responses to vaccination. While reduced antibody responses to primary SARS-CoV-2 vaccination in anti-CD20–treated patients are well documented, the durability of these responses and the effects of booster vaccination remain incompletely understood. In this prospective single-center...

Topics

Open a Topic to create a Post that cites this publication.

Identifiers and source

Literature Corpus work
bae579b5-1551-5667-ac37-c1a53dac7c44
DOI
10.21203/rs.3.rs-9784622/v1
Open publication

Related research

Semantic proximity does not establish scientific evidence.

Click a neighbor to travelStep 1 · 12 closest
Interactive article relationship graphSelect a related publication card to move it into the centre and load its closest explainable connections. Solid lines are source-backed structured connections. Dashed lines are semantic discovery signals and are not scientific evidence.
Longitudinal follow-up of SARS-CoV-2 vaccine- induced antibody responses in patients with multiple sclerosis treated with anti-CD20 therapyDOI 10.21203/rs.3.rs-9784622/v1
Durable T cell immunity to COVID-19 vaccines in MS patients on B cell depletion therapySemantic proximity
Distinct Patterns of Humoral and Cellular Immune Responses Following SARS-CoV-2 mRNA Vaccination in Patients With Immune-Mediated Neurological Disorders on Anti-CD20 Therapy: A Prospective Cohort StudySemantic proximity
Altered cellular and humoral immune responses following SARS-CoV-2 mRNA vaccination in patients with multiple sclerosis on anti-CD20 therapySemantic proximity
Humoral immune responses remain quantitatively impaired but improve qualitatively in anti-CD20 treated patients with multiple sclerosis after three or four COVID-19 vaccinationsSemantic proximity
Preserved T-cell Response in anti-CD20 Treated Multiple Sclerosis Patients Following SARS-CoV-2 VaccinationSemantic proximity
Patients treated with anti-CD20 therapy can mount robust T cell responses to mRNA-based COVID-19 vaccinesSemantic proximity
Effect of different disease-modifying therapies on humoral response to BNT162b2 vaccine in Sardinian multiple sclerosis patientsSemantic proximity
The immune response to Covid-19 mRNA vaccination among Lymphoma patients receiving anti-CD20 treatmentSemantic proximity
Immune profiling of COVID-19 vaccine responses in people with multiple sclerosis on B cell-depleting therapySemantic proximity
Humoral Immune Response Following SARS-CoV-2 mRNA Vaccination and Infection in Pediatric-Onset Multiple SclerosisSemantic proximity
Immune responses and disease biomarker long-term changes following COVID-19 mRNA vaccination in a cohort of rheumatic disease patientsSemantic proximity
B- and T-cell Specific Responses to Vaccination against SARS-CoV-2 in Anti-CD20 Treated Patients with Relapsing-Remitting or Progressive Form of Multiple Sclerosis Reveal Immunosenescent FeaturesSemantic proximity
Select a neighboring publication to make it the new centre.